United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - 1. for the treatment of congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency. it is recommended that the diagnosis of congestive heart failure be confirmed by radiographs or diuretic responsiveness. treatment should be initiated only in symptomatic cases which will benefit from increased myocardial contractility (positive inotropy). 2. to delay the time of onset of congestive heart failure or sudden death in doberman pinscher dogs with clinically asymptomatic dilated cardiomyopathy. clinically asymptomatic dilated cardiomyopathy is characterized by an increase in left ventricular end-systolic and end-diastolic diameter and should be diagnosed by means of a comprehensive cardiac examination (including echocardiographic examination and possibly holter monitoring). vetmedin® capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic ste

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - pimobendan - capsules hard - 1.25 milligram - canine - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - pimobendan - capsules hard - 2.5 milligram - canine - cardiovascular

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - pimobendan - capsules hard - 1.25 milligram - cardiovascular - canine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - pimobendan - capsules hard - 2.5 milligram - cardiovascular - canine

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim ltd - pimobendan - capsules hard - 5 milligram - pimobendane - canine - cardiovascular

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - vetmedin-ca1 (pimobendan) is indicated for the delay of onset of congestive heart failure in dogs with stage b2 preclinical myxomatous mitral valve disease (2019 acvim consensus statement1 ). stage b2 preclinical myxomatous mitral valve disease (mmvd) refers to dogs with asymptomatic mmvd that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly. do not administer vetmedin-ca1 in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. do not administer vetmedin-ca1 to dogs with stage a or b1 preclinical mmvd (2019 acvim consensus statement) due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to vetmedin-ca1.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - pimobendan 1.25 mg - vetmedin (pimobendan) is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (mmvd) or dilated cardiomyopathy (dcm). vetmedin is indicated for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. vetmedin should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. user safety warnings: not for use in humans. keep this and all medications out of reach of children. consult a physician in case of accidental ingestion by humans. animal safety warnings: keep vetmedin in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. only for use in dogs with clinical evidence of heart failure. at 3 and 5 times the recommended dosage, administered over a 6-month

Spain - English - HMA (Heads of Medicines Agencies)

boehringer ingelheim espaÑa - pimobendan 10 mg - capsule, hard - dogs non food - pimobendane

Portugal - English - HMA (Heads of Medicines Agencies)

boehringer ingelheim espaÑa - pimobendan 10 mg - capsule, hard - dogs non food - pimobendane